Payment overview · 2025
General Payments
$289.39
14 reported records · 7 companies
Healthcare provider profile · identity verified
Frank A Rich, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · YOUNGSTOWN, OH · NPI 1366419277
Verified facts
What the public records show
CMS Open Payments records show Frank A Rich, D.O. received $289.39 in general payments during 2025 across 14 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 576 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Xtandi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $86.53 | 29.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.68 | 16.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.08 | 13.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.14 | 12.8% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $31.74 | 11.0% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.67 | 10.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.55 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $289.39 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $69.88 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.68 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $40.08 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.39 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $31.74 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $29.67 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 576 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 104 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
104 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
576 | 55 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 758 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 687 | 83 |
| Eliquis | Apixaban | 576 | 55 |
| Mirtazapine | Mirtazapine | 515 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 505 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 502 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 450 | 62 |
| Lisinopril | Lisinopril | 382 | 50 |
| Metformin Hcl | Metformin Hcl | 376 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 351 | 38 |
| Meloxicam | Meloxicam | 338 | 57 |
| Bumetanide | Bumetanide | 331 | 36 |
| Rivastigmine | Rivastigmine Tartrate | 322 | 17 |
| Memantine Hcl | Memantine Hcl | 321 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 320 | 30 |
| Divalproex Sodium | Divalproex Sodium | 313 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 306 | 75 |
| Furosemide | Furosemide | 303 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 302 | 33 |
| Gabapentin | Gabapentin | 299 | 39 |
| Buspirone Hcl | Buspirone Hcl | 284 | 32 |
| Sertraline Hcl | Sertraline Hcl | 240 | 43 |
| Losartan Potassium | Losartan Potassium | 239 | 32 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 217 | 34 |
| Donepezil Hcl | Donepezil Hcl | 204 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 176 | 26 |
| Simvastatin | Simvastatin | 167 | 32 |
| Carvedilol | Carvedilol | 149 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 149 | 81 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 142 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 141 | 17 |
| Omeprazole | Omeprazole | 128 | 28 |
| Montelukast Sodium | Montelukast Sodium | 118 | 17 |
| Warfarin Sodium | Warfarin Sodium | 118 | suppressed |
| Potassium Chloride | Potassium Chloride | 117 | 15 |
| Risperidone | Risperidone | 115 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 114 | 14 |
| Sucralfate | Sucralfate | 105 | 13 |
| Jardiance | Empagliflozin | 104 | 13 |
| Allopurinol | Allopurinol | 101 | 19 |
| Levetiracetam | Levetiracetam | 93 | 13 |
| Trazodone Hcl | Trazodone Hcl | 93 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 89 | 13 |
| Entresto | Sacubitril/Valsartan | 88 | suppressed |
| Famotidine | Famotidine | 88 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 85 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 84 | suppressed |
| Atenolol | Atenolol | 82 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 81 | suppressed |
| Prednisone | Prednisone | 80 | 15 |
| Methocarbamol | Methocarbamol | 78 | 21 |
| Glipizide | Glipizide | 76 | suppressed |
| Spironolactone | Spironolactone | 75 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 23 |
| Azithromycin | Azithromycin | 69 | 48 |
| Cefdinir | Cefdinir | 68 | 54 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 68 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 66 | suppressed |
| Cephalexin | Cephalexin | 61 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | suppressed |
| Ibuprofen | Ibuprofen | 59 | 27 |
| Lactulose | Lactulose | 59 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 56 | suppressed |
| Valsartan | Valsartan | 54 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 12 |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 51 | suppressed |
| Primidone | Primidone | 51 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 50 | suppressed |
| Clozapine | Clozapine | 47 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | suppressed |
| Rivastigmine | Rivastigmine | 47 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 46 | suppressed |
| Budesonide | Budesonide | 45 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 43 | 12 |
| Glycopyrrolate | Glycopyrrolate | 43 | suppressed |
| Latanoprost | Latanoprost | 43 | 11 |
| Xtandi | Enzalutamide | 43 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | suppressed |
| Synthroid | Levothyroxine Sodium | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Olanzapine | Olanzapine | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 40 | suppressed |
| Glimepiride | Glimepiride | 38 | suppressed |
| Lidocaine | Lidocaine | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | suppressed |
| Lorazepam | Lorazepam | 37 | 12 |
| Lithium Carbonate | Lithium Carbonate | 36 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 36 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 35 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 33 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 22 |
| Benztropine Mesylate | Benztropine Mesylate | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 15 |
| Mupirocin | Mupirocin | 29 | 27 |
| Torsemide | Torsemide | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 28 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Etodolac | Etodolac | 27 | suppressed |
| Paliperidone Er | Paliperidone | 27 | suppressed |
| Acarbose | Acarbose | 26 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 26 | 11 |
| Baclofen | Baclofen | 26 | suppressed |
| Haloperidol | Haloperidol | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Trospium Chloride | Trospium Chloride | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Cimetidine | Cimetidine | 24 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 19 |
| Gemtesa | Vibegron | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 22 |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Methimazole | Methimazole | 22 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 11 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Ramelteon | Ramelteon | 21 | suppressed |
| Amikacin Sulfate | Amikacin Sulfate | 20 | suppressed |
| Dofetilide | Dofetilide | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 16 |
| Colchicine | Colchicine | 18 | suppressed |
| Leflunomide | Leflunomide | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Movantik | Naloxegol Oxalate | 17 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 12 |
| Sodium Chloride | 0.9 % Sodium Chloride | 16 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 15 | 15 |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Briviact | Brivaracetam | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Acetylcysteine | Acetylcysteine | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Mexiletine Hcl | Mexiletine Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Oxaprozin | Oxaprozin | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $289.39 · 14 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, ELIQUIS, FARXIGA, Flucelvax, JARDIANCE, KRYSTEXXA, MOUNJARO, NEXLETOL, NURTEC ODT, ZAVZPRET, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error